CTOs on the Move


 
MSI Methylation Sciences Inc. (“MSI”) is a clinical-stage pharmaceutical company focused on developing new products based on molecules which have clinical proof of concept but which have yet to be exploited in the major pharmaceutical markets. MSI`s focus is in the CNS space where clinical proof of concept is key to reducing the drug development risk. Our lead product candidate, Strada™, is based upon Ademetionine, a naturally occurring molecule produced throughout the body, where it plays a vital role in the one-carbon cycle. Our disease indication is Major Depressive Disorder (MDD).
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

MSI raised $30M on 10/07/2016

Similar Companies

US Med

US Med, LLC is a Irving, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biomedical Systems

Biomedical Systems offers our Sponsors flexible and responsive customization to their unique protocol needs. We have the ability to leverage our company-wide offerings to enhance our Quality, Regulatory, Data Management, IT, and other support functions.

Hilsinger Company dba Hilco USA

Hilsinger Company L.P. dba Hilco USA is a Plainville, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Carefirst Blue Cross Blue Shield

Carefirst Blue Cross Blue Shield is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Brooks Rehabilitation

Our foundation supports many programs throughout the Brooks System of Care, including clinical research, adaptive sports and wellness, school re-entry, and free care for those who need it most. Our Volunteer Services department provides an opportunity for personal growth, education, and service to others. Our goal is to meet the needs of our volunteers while carrying out our vision of providing world-class service to our patients. Volunteer assignments are made according to interest, availability, and the skills needed to fulfill task requirements.